Unicycive Therapeutics is a biotechnology company focused on developing treatments for certain medical conditions. Co.'s existing development programs are focused on the development of two therapies: Renazorb, for treatment of hyperphosphatemia in patients with chronic kidney disease (CKD); and UNI 494, for treatment of acute kidney injury (AKI). CKD is the gradual loss of kidney function that can get worse over time leading to lasting damage. AKI is a sudden episode of kidney failure or kidney damage (within the first 90 days of injury). After 90 days, the patient is considered to have progressed into CKD. The UNCY average annual return since 2021 is shown above.
The Average Annual Return on the UNCY average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether UNCY average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the UNCY average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|